RESUMEN
UNLABELLED: Treatment of phenylketonuria involves a restriction in the intake of natural proteins. This can lead to growth impairment. Weight, height and body mass index of 109 hyperphenylalaninemic patients (mild hyperphenylalaninemia (HPA) and phenylketonuria (PKU)) were determined from birth until 18 years, every 6 months, and differences to the healthy population, depending on the age, sex and phenotype, were analyzed. Data collection was longitudinal retrospective during 31 years. Statistical analysis of z-score values was performed by advanced statistical tools. Long-term evolution of anthropometric z-scores showed no significant statistical differences between PKU and mild HPA individuals, according to the general population. For PKU individuals, height is slightly lower and weight slightly higher than in the healthy population, but differences are smaller than one standard deviation. Nevertheless, over-time evolutions of female height z-scores are different in each type of pathology, with a crossover between 8 and 12 years (p = 0.0186). CONCLUSIONS: It is nowadays possible to achieve a long-term normal growth in PKU patients with appropriate dietary treatment. There is however an acceleration of growth up to 8 years old for PKU female patients that leads to a slightly lower final height. Detection of this behaviour was possible by using nonlinear mixed effects models.
Asunto(s)
Desarrollo del Adolescente/fisiología , Desarrollo Infantil/fisiología , Dieta con Restricción de Proteínas , Fenilcetonurias/dietoterapia , Adolescente , Estatura/fisiología , Índice de Masa Corporal , Peso Corporal/fisiología , Niño , Preescolar , Femenino , Humanos , Lactante , Recién Nacido , Estudios Longitudinales , Masculino , Dinámicas no Lineales , Estudios RetrospectivosRESUMEN
BACKGROUND & AIMS: Nutritional supplementation with polyunsaturated fatty acids is important in preterm infants neurodevelopment, but it is not known if the omega-6/omega-3 ratio affects this process. This study was designed to determine the effects of a balanced contribution of arachidonic acid in very preterm newborns fed with formula milk. METHODS: This was a randomized trial, in which newborns <1500 g and/or <32 weeks gestational age were assigned to one of two groups, based on the milk formula they would receive during the first year of life. Initially, 60 newborns entered the study, but ultimately, group A was composed of 24 newborns, who were given formula milk with an ω-6/ω-3 ratio of 2/1, and Group B was composed of 21 newborns, given formula milk with an ω-6/ω-3 ratio of 1/1. The infants were followed up for two years: growth, visual-evoked potentials, brainstem auditory-evoked potentials, and plasma fatty acids were periodically measured, and psychomotor development was assessed using the Brunet Lézine scale at 24 months corrected age. A control group, for comparison of Brunet Lézine score, was made up of 25 newborns from the SEN1500 project, who were fed exclusively with breast milk. RESULTS: At 12 months, arachidonic acid values were significantly higher in group A than in group B (6.95 ± 1.55% vs. 4.55 ± 0.78%), as were polyunsaturated fatty acids (41.02 ± 2.09% vs. 38.08 ± 2.32%) achieved a higher average. Group A achieved a higher average Brunet Lézine score at 24 months than group B (99.9 ± 9 vs. 90.8 ± 11, p =0.028). The Brunet Lézine results from group A were compared with the control group results, with very similar scores registered between the two groups (99.9 ± 9 vs. 100.5 ± 7). There were no significant differences in growth or evoked potentials between the two formula groups. CONCLUSIONS: Very preterm infants who received formula with an ω-6/ω-3 ratio of 2/1 had higher blood levels of essential fatty acids during the first year of life, and better psychomotor development, compared with very preterm newborns who consumed formula with an ω-6/ω-3 of 1/1. Therefore, formula milk with an arachidonic acid quantity double that of docosahexaenoic acid should be considered for feeding very preterm infants. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT02503020.
Asunto(s)
Ácido Araquidónico/administración & dosificación , Fenómenos Fisiológicos Nutricionales del Lactante , Recien Nacido Prematuro/crecimiento & desarrollo , Ácido Araquidónico/análisis , Desarrollo Infantil/efectos de los fármacos , Preescolar , Suplementos Dietéticos , Método Doble Ciego , Ácidos Grasos/sangre , Ácidos Grasos Omega-6/administración & dosificación , Femenino , Estudios de Seguimiento , Edad Gestacional , Humanos , Lactante , Fórmulas Infantiles/química , Recién Nacido , Masculino , Leche Humana , Estudios Prospectivos , Factores de RiesgoRESUMEN
Current advances in DNA sequencing technologies are dropping down sequencing cost while increasing throughput at a pace never shown before. Past-decade great milestones, as the establishment of a reference human genome (amongst others) and large-scale human genetic variation study in the 1000 Genome project are, in conjunction with the use of these techniques, triggering advances in many areas of basic and applied science. These tools, stored in and combined with the vast amount of information present in biological online databases are, with the use of automated interpretation and analysis tools, allowing the fulfillment of increasingly ambitious studies in many areas and also are democratizing the access to information, interpretation and technologies, being the first opportunity for researchers to assess the influence of genetics in complex events as multifactorial diseases, evolutionary studies, metagenomics, transcriptomics, etc. In this review, we present the current state of the art of these technologies, focusing on second generation sequencing, from sample and library preparation to sequencing chemistries and bioinformatic software available for final data analysis and visualisation, with its possible applications. We also make an overview of first and third generation, due to its historical importance and for being the upcoming future tools for genetic analysis, respectively.
Asunto(s)
Genoma Humano , Polimorfismo de Nucleótido Simple/genética , Análisis de Secuencia de ADN/métodos , Biología Computacional , Humanos , Programas InformáticosRESUMEN
There is a compromised bone mass in phenylketonuria patients compared with normal population, but the mechanisms responsible are still a matter of investigation. In addition, tetrahydrobiopterin therapy is a new option for a significant proportion of these patients and the prevalence of mineral bone disease (MBD) in these patients is unknown. We conducted a cross-sectional observational study including 43 phenylketonuric patients. Bone densitometry, nutritional assessment, physical activity questionnaire, biochemical parameters, and molecular study were performed in all patients. Patients were stratified by phenotype, age and type of treatment. The MBD prevalence in phenylketonuria was 14%. Osteopenic and osteoporotic (n=6 patients) had an average daily natural protein intake significantly lower than the remaining (n=37) patients with PKU (14.33 ± 8.95 g vs 21.25 ± 20.85 g). Besides, a lower body mass index was found. There were no statistical differences in physical activity level, calcium, phosphorus and fat intake, and in phenylalanine, vitamin D, paratohormone, docosahexaenoic and eicosapentaenoic acid blood levels. Mutational spectrum was found in up to 30 different PAH genotypes and no relationship was established among genotype and development of MBD. None of the twelve phenylketonuric patients treated with tetrahydrobiopterin (27.9%), for an average of 7.1 years, developed MBD. Natural protein intake and blood levels of eicosapentaenoic acid were significantly higher while calcium intake was lower in these patients. This study shows that the decrease in natural protein intake can play an important role in MBD development in phenylketonuric patients. Therapy with tetrahydrobiopterin allows a more relaxed protein diet, which is associated with better bone mass.
Asunto(s)
Desmineralización Ósea Patológica/metabolismo , Enfermedades Óseas Metabólicas/metabolismo , Huesos/metabolismo , Proteínas en la Dieta/administración & dosificación , Minerales/administración & dosificación , Osteoporosis/metabolismo , Fenilcetonurias/metabolismo , Adolescente , Adulto , Biopterinas/análogos & derivados , Biopterinas/farmacología , Biopterinas/uso terapéutico , Índice de Masa Corporal , Desmineralización Ósea Patológica/complicaciones , Desmineralización Ósea Patológica/tratamiento farmacológico , Desmineralización Ósea Patológica/patología , Densidad Ósea/efectos de los fármacos , Enfermedades Óseas Metabólicas/complicaciones , Enfermedades Óseas Metabólicas/tratamiento farmacológico , Enfermedades Óseas Metabólicas/patología , Huesos/efectos de los fármacos , Huesos/patología , Calcio/metabolismo , Niño , Estudios Transversales , Ácido Eicosapentaenoico/metabolismo , Femenino , Humanos , Masculino , Actividad Motora , Mutación , Osteoporosis/complicaciones , Osteoporosis/tratamiento farmacológico , Osteoporosis/patología , Fenilalanina Hidroxilasa/genética , Fenilalanina Hidroxilasa/metabolismo , Fenilcetonurias/complicaciones , Fenilcetonurias/tratamiento farmacológico , Fenilcetonurias/patología , Factores de Riesgo , Encuestas y CuestionariosRESUMEN
Persistent hypermethioninemia due to mutations in the MAT1A gene is often found during newborn screening (NBS) for homocystinuria due to cystathionine beta-synthase deficiency, however, outcomes and optimal management for these patients are not well established. We carried out a multicenter study of MAT I/III-deficient patients detected by NBS in four of the Spanish regional NBS programs. Data evaluated during NBS and follow-up for 18 patients included methionine and total homocysteine levels, clinical presentation parameters, genotypes, and development quotients. The birth prevalence was 1:1:22,874. At detection 16 of the 18 patients exhibited elevations of plasma methionine above 60 µmol/L (mean 99.9 ± 38 µmol/L) and the mean value in confirmation tests was 301 µmol/L (91-899) µmol/L. All patients were asymptomatic. In four patients with more markedly elevated plasma methionines (>450 µmol/L) total homocysteine values were slightly elevated (about 20 µmol/L). The average follow-up period was 3 years 7 months (range: 2-123 months). Most patients (83%) were heterozygous for the autosomal dominant Arg264His mutation and, with one exception, presented relatively low circulating methionine concentrations (<400 µM). Additional mutations identified in patients with mean confirmatory plasma methionines above 400 µM were Arg199Cys, Leu355Arg, and a novel mutation, Thr288Ala. During continued follow-up, the patients have been asymptomatic, and, to date, no therapeutic interventions have been utilized. Therefore, the currently available evidence shows that hypermethioninemia due to heterozygous MAT1A mutations such as Arg264His is a mild condition for which no treatment is necessary.
Asunto(s)
Errores Innatos del Metabolismo de los Aminoácidos/diagnóstico , Errores Innatos del Metabolismo de los Aminoácidos/metabolismo , Metionina Adenosiltransferasa/deficiencia , Femenino , Estudios de Seguimiento , Glicina N-Metiltransferasa/deficiencia , Humanos , Recién Nacido , Masculino , Metionina/sangre , Metionina Adenosiltransferasa/genética , Metionina Adenosiltransferasa/metabolismo , Mutación , Tamizaje NeonatalRESUMEN
RATIONALE: Rapid and specific screening methods to detect abnormal metabolites in biological fluids are important for the diagnosis of many Inborn Errors of Metabolism (IEM). In Galicia (N.W. Spain), where newborn screening (NBS) has long used both blood and urine dried samples, an expanded NBS by tandem mass spectrometry (MS/MS) begun in July 2000 analyzing amino acids and acylcarnitines in blood. The purpose of this study is the development of methods to widen and to complement the present NBS with the study of the selected metabolites in urine. METHODS: We studied and optimized the fragmentation of a total of 96 marking compounds of IEM, as well as 34 isotopically labeled internal standards (IS). The isobaric interferences were resolved with the use of alternative fragmentation in 14 of the 28 groups found. The methods were validated for 68 compounds following the recommendations of the NCCLS. RESULTS: We have developed electrospray ionization (ESI)- MS/MS methods in positive and negative ionization modes to detect selected metabolites in urine. The study was performed by direct injection of amino acids and acylcarnitines in positive mode, and organic acids, acylglycines, purines and pyrimidines in negative mode. Run times were 2.5 and 2.6 min, respectively, allowing the daily analysis of a high number of samples. CONCLUSIONS: The validated methods were proved effective for the simultaneous study of a large number of metabolites which are commonly present in urine samples and are used for detecting IEM. The evaluation was done by searching diagnostic profiles with multiple markers to increase sensitivity and specificity (e.g., acylcarnitines plus amino acids) or with specific urine markers (cystine, homogentisic acid, sialic acid, N-acetylaspartic acid, etc.).
Asunto(s)
Errores Innatos del Metabolismo/orina , Espectrometría de Masa por Ionización de Electrospray/métodos , Espectrometría de Masas en Tándem/métodos , Biomarcadores/orina , Humanos , Iones/orina , Compuestos Orgánicos/orina , Reproducibilidad de los Resultados , Sensibilidad y EspecificidadRESUMEN
Newborn screening (NBS) by tandem mass spectrometry started in Galicia (Spain) in 2000. We analyse the results of screening and clinical follow-up of inborn errors of metabolism (IEM) detected during 10 years. Our programme basically includes the disorders recommended by the American College of Medical Genetics. Since 2002, blood and urine samples have been collected from every newborn on the 3rd day of life; before then, samples were collected between the 5th and 8th days. Newborns who show abnormal results are referred to the clinical unit for diagnosis and treatment. In these 10 years, NBS has led directly to the identification of 137 IEM cases (one per 2060 newborns, if 35 cases of benign hyperphenylalaninemia are excluded). In addition, 33 false positive results and 10 cases of transitory elevation of biomarkers were identified (making the positive predictive rate 76.11%), and 4 false negative results. The use of urine samples contributed significantly to IEM detection in 44% of cases. Clinical symptoms appeared before positive screening results in nine patients (6.6%), four of them screened between days 5 and 8. The death rate was 2.92%; of the survivors, 95.5% were asymptomatic after a mean observation period of 54 months, and only two had an intellectual/psychomotor development score less than 85. Compared to other studies, a high incidence of type I glutaric aciduria was detected, one in 35,027 newborns. This report highlights the benefits of urine sample collection during screening, and it is the first study on expanded newborn screening results in Spain.
Asunto(s)
Errores Innatos del Metabolismo/diagnóstico , Tamizaje Neonatal , Biomarcadores/orina , Reacciones Falso Positivas , Estudios de Seguimiento , Humanos , Incidencia , Recién Nacido , Errores Innatos del Metabolismo/mortalidad , Errores Innatos del Metabolismo/orina , España/epidemiologíaRESUMEN
This study aims to quantify concentrations of minerals and trace elements in human milk (HM) and infant formula (IF) and evaluate associations with medical, social, environmental, and demographic variables. A prospective, case series study of 170 nursing mothers was made. HM samples were obtained from full-term (colostrum, intermediate and mature HM) and preterm (mature HM) mothers. Variables of interest were assessed by a questionnaire. For comparison, IF samples (n = 30) were analyzed in a cross-sectional study. Concentrations of 35 minerals, essential and toxic trace elements were quantified, 5 for the first time: thallium in HM and IF; strontium in preterm HM; and gallium, lithium and uranium in IF. In preterm and full-term HM, levels of selenium (p < 0.001) were significantly lower than recommended and were associated with low birth weight (p < 0.002). Cesium and strontium concentrations were significantly higher than recommended (p < 0.001). Associations were observed between arsenic and residence in an urban area (p = 0.013), and between lead and smoking (p = 0.024) and well-water consumption (p = 0.046). In IF, aluminum, vanadium, and uranium levels were higher than in HM (p < 0.001); uranium, quantified for the first time, was 100 times higher in all types of IF than in HM. Our results indicate that concentrations of most trace elements were within internationally accepted ranges for HM and IF. However, preterm infants are at increased risk of nutritional deficiencies and toxicity. IF manufacturers should reduce the content of toxic trace elements.
Asunto(s)
Leche Humana/química , Minerales/análisis , Embarazo/estadística & datos numéricos , Oligoelementos/análisis , Adulto , Estudios Transversales , Femenino , Humanos , Fórmulas Infantiles/química , Recién Nacido , Noxas/análisis , Nacimiento Prematuro/epidemiología , Factores Socioeconómicos , España , Adulto JovenRESUMEN
Homocystinuria due to cystathionine ß-synthase deficiency or "classical homocystinuria" is a rare autosomal recessive condition resulting in altered sulfur metabolism with elevated methionine and homocysteine in plasma and homocystine in urine. This condition is characterized by a high clinical heterogeneity, which contributes to late clinical diagnosis, usually only made after irreversible damage has occurred. Treatment is effective if started before clinical symptoms. The analysis of methionine levels by tandem mass spectrometry (MS/MS) allows the newborn screening for homocystinuria, but false-positive results can be frequently obtained and lead to the unwanted identification of methionine adenosyl transferase (MAT I/III) deficiency. This latter condition is biochemically characterized by isolated persistent hypermethioninemia, accompanied in some individuals with slightly elevated levels of homocysteine in plasma. A dominant form of MAT I/III deficiency, associated with mutation p.R264H, seems to be very frequent in the Iberian Peninsula and usually has a clinically benign course. Both these metabolic disorders are screened in Galicia and Portugal since the introduction of the MS/MS technology, in 2000 and 2004, respectively, resulting in the identification of three patients with classical homocystinuria and 44 patients with MAT I/III deficiency. All but one heterozygous parent of MAT I/III patients, identified with the p.R264H mutation, are healthy adults around the age of 30/40. The implementation of a second-tier test for homocysteine in dried blood spots would considerably reduce the number of MAT I/III-deficient patients identified and improve the specificity and positive predictive value for classical homocystinuria screening.
RESUMEN
BACKGROUND AND OBJECTIVE: Mineral bone disease is more common in phenylketonuric patients. The objectives of this study were to determine the usefulness of biochemical bone markers to identify phenylketonuric patients with mineral bone disease (MBD) and know the underlying bone remodeling alterations. PATIENTS AND METHOD: Cross-sectional study of 43 phenylketonuric patients>7 years (range: 7.1-41 years). A nutritional survey was performed and bone alkaline phosphatase (BAP), procollagen type 1 N-terminal propeptide (PNP-1), beta-crosslaps and ratio calcium/creatinine in urine were determined. RESULTS: A percentage of 20.9 of patients had pathological biochemical bone markers, 90% of them being adults. BAP was decreased in 70% of them and beta-crosslaps in 42.8%. BAP values were more often pathological in phenylketonuric patients with a late diagnosis (41.7 vs. 10.7%; P<.05) and in patients with MBD (60 vs. 14.3%; P<.05). PNP-1 values and calcium/creatinine were similar among all phenylketonuric patients regardless of presenting MBD, late diagnosis or tetrahydrobipterin treatment (enzyme cofactor). Patients with decreased BAP and beta-crosslaps had lower natural protein intake: BAP (0.21 ± 0.13 vs. 0.65 ± 0.65 g/kg; P<.05); beta-crosslaps (0.29 ± 0.23 vs. 0.65 ± 0.66 g/kg; P<.05). None of the tetrahydrobiopterin treated patients showed altered values of BAP, PNP-1 or calcium/creatinine. CONCLUSIONS: Adult phenylketonuric patients with lower natural protein intake tend to have lower values of BAP, which is a marker that may be useful to identify patients at risk for MBD.
Asunto(s)
Biomarcadores/metabolismo , Enfermedades Óseas Metabólicas/diagnóstico , Remodelación Ósea/fisiología , Fenilcetonurias/complicaciones , Adolescente , Adulto , Biomarcadores/sangre , Biomarcadores/orina , Enfermedades Óseas Metabólicas/sangre , Enfermedades Óseas Metabólicas/orina , Niño , Estudios Transversales , Femenino , Humanos , Masculino , Adulto JovenRESUMEN
We describe here a 34 months child, practically asymptomatic which presented with high levels of free sialic acid in urine by biochemical detection in second-tier tests newborn screening and with two disease causing mutations in SLC17A5 gene. SLC17A5 mutation analysis showed p.Tyr306* previously described and the novel mutation p.Leu167Pro. This early onset diagnosis allowed us to perform a fast and accurate genetic counseling to the family, helped to better understanding the natural history of this rare disease and probably it could promote cost reduction in future diagnostic tests in the hypothetic case of starting symptoms without diagnosis established. Moreover, an early diagnosis could save family from a long period of time until achieving a definitive diagnostic and to develop an early symptomatic and supportive management of patient to attenuate, as much as possible, disease complications. But, above all, this case illustrates the huge ethical dilemma which arises from any secondary finding (second tier) in newborn screening.
Asunto(s)
Diagnóstico Precoz , Tamizaje Neonatal , Enfermedad por Almacenamiento de Ácido Siálico/diagnóstico , Secuencia de Aminoácidos , Análisis Mutacional de ADN , Femenino , Humanos , Hallazgos Incidentales , Lactante , Recién Nacido , Datos de Secuencia Molecular , Mutación , Ácido N-Acetilneuramínico/sangre , Ácido N-Acetilneuramínico/orina , Transportadores de Anión Orgánico/química , Transportadores de Anión Orgánico/genética , Alineación de Secuencia , Enfermedad por Almacenamiento de Ácido Siálico/genética , Enfermedad por Almacenamiento de Ácido Siálico/metabolismo , Simportadores/química , Simportadores/genéticaRESUMEN
BACKGROUND: Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) is the most common inherited defect in the mitochondrial fatty acid oxidation pathway, resulting in significant morbidity and mortality in undiagnosed patients.Newborn screening (NBS) has considerably improved MCADD outcome, but the risk of complication remains in some patients. The aim of this study was to evaluate the relationship between genotype, biochemical parameters and clinical data at diagnosis and during follow-up, in order to optimize monitoring of these patients. METHODS: We carried out a multicenter study in southwest Europe, of MCADD patients detected by NBS. Evaluated NBS data included free carnitine (C0) and the acylcarnitines C8, C10, C10:1 together with C8/C2 and C8/C10 ratios, clinical presentation parameters and genotype, in 45 patients. Follow-up data included C0 levels, duration of carnitine supplementation and occurrence of metabolic crises. RESULTS: C8/C2 ratio and C8 were the most accurate biomarkers of MCADD in NBS. We found a high number of patients homozygous for the prevalent c.985A > G mutation (75%). Moreover, in these patients C8, C8/C10 and C8/C2 were higher than in patients with other genotypes, while median value of C0 was significantly lower (23 µmol/L vs 36 µmol/L).The average follow-up period was 43 months. To keep carnitine levels within the normal range, carnitine supplementation was required in 82% of patients, and for a longer period in patients homozygotes for the c.985A>G mutation than in patients with other genotypes (average 31 vs 18 months). Even with treatment, median C0 levels remained lower in homozygous patients than in those with other genotypes (14 µmol/L vs 22 µmol/L).Two patients died and another three suffered a metabolic crisis, all of whom were homozygous for the c.985 A>G mutation. CONCLUSIONS: Our data show a direct association between homozygosity for c.985A>G and lower carnitine values at diagnosis, and a higher dose of carnitine supplementation for maintenance within the normal range. This study contributes to a better understanding of the relationship between genotype and phenotype in newborn patients with MCADD detected through screening which could be useful in improving follow-up strategies and clinical outcome.
Asunto(s)
Acil-CoA Deshidrogenasa/deficiencia , Cardiomiopatías/epidemiología , Carnitina/sangre , Carnitina/deficiencia , Hiperamonemia/epidemiología , Errores Innatos del Metabolismo Lipídico/diagnóstico , Enfermedades Musculares/epidemiología , Tamizaje Neonatal/métodos , Cardiomiopatías/diagnóstico , Cardiomiopatías/tratamiento farmacológico , Carnitina/administración & dosificación , Carnitina/análogos & derivados , Suplementos Dietéticos , Femenino , Estudios de Asociación Genética , Genotipo , Homocigoto , Humanos , Hiperamonemia/diagnóstico , Hiperamonemia/tratamiento farmacológico , Incidencia , Recién Nacido , Errores Innatos del Metabolismo Lipídico/tratamiento farmacológico , Errores Innatos del Metabolismo Lipídico/epidemiología , Masculino , Enfermedades Musculares/diagnóstico , Enfermedades Musculares/tratamiento farmacológico , Fenotipo , Prevalencia , España/epidemiología , Complejo Vitamínico B/administración & dosificación , Complejo Vitamínico B/sangreRESUMEN
The purpose of this paper is to develop an easy and quick on-line selenium speciation method (LC-UV-HG-AFS) in cow milk obtained after different supplementation to cow feed. This study focuses on selenium speciation in cow milk after the use of different selenium species (organic selenium as selenised yeast and inorganic selenium as sodium selenite) in the supplementation of forages. Separation was carried out on a muBondapack C(18) column with the positively charged ion-pairing agent tetraethylammonium chloride in the mobile phase. The optimization of pre-reduction conditions was carried out; this step was done with UV irradiation and a heating block to improve the reduction of the different Se-compounds. Variables such as exposure time, hydrochloric acid concentration and temperature were studied. The detection limits for SeCyst(2), Se(IV), SeMet and Se(VI) were 0.4, 0.5, 0.9 and 1.0mugl(-1), respectively. The proposed method was applied to cow milk samples. The milk samples obtained after an organic supplementation of feeding as selenised yeast present three species of selenium, SeCyst2, Se(IV) and SeMet, while only SeCyst2 and Se(IV) are present in milk samples obtained after an inorganic supplementation of feeding.
RESUMEN
The purpose of the work described in this paper was to develop an easy and quick in-vitro method for comparing the bioavailability of selenium in cows' milk after different cow feed. The study focuses on bioavailability differences resulting from the use of different selenium species (organic selenium as selenised yeast and sodium selenite) for supplementation of forage. A procedure for determination of selenium in cows' milk and dialysates, by hydride-generation atomic-fluorescence spectrometry (HG-AFS) after microwave-assisted acid digestion, was optimised. The results show it is possible to obtain cows' milk enriched with selenium at different concentration without altering the original composition of the milk. The bioavailability was statistically greater for cows' milk obtained after supplementation of forage with organic selenium at levels of 0.4 and 0.5 microg Se g(-1) than for that obtained after supplementation with inorganic and organic selenium at levels of 0.2 and 0.3 microg Se g(-1).
Asunto(s)
Alimentación Animal/análisis , Dieta/veterinaria , Leche/química , Selenio/análisis , Selenio/farmacocinética , Fenómenos Fisiológicos Nutricionales de los Animales , Animales , Disponibilidad Biológica , Bovinos , Suplementos Dietéticos , Alimentos Fortificados/análisis , Selenio/administración & dosificación , Selenio/químicaRESUMEN
A procedure has been developed for determining the selenium in cow's milk using hydride generation-atomic absorption spectrometry (HG-AAS) following microwave-assisted acid digestion. The selenium distributions in milk whey, fat and micellar casein phases were studied after separating the different phases by ultracentrifugation and determining the selenium in all of them. The detection limits obtained by HG-AAS for the whole milk, milk whey and micellar casein were 0.074, 0.065 and 0.075 microg l(-1), respectively. The accuracy for the whole milk was checked by using a Certified Reference Material CRM 8435 whole milk powder from NIST, and the analytical recoveries for the milk whey and casein micelles were 100.9 and 96.9%, respectively. A mass balance study of the determination of selenium in the different milk phases was carried out, obtaining values of 95.5-100.8%. The total content of selenium was determined in 37 milk samples from 15 different manufacturers, 19 whole milk samples and 18 skimmed milk samples. The selenium levels found were within the 8.5-21 microg l(-1) range. The selenium distributions in the different milk phases were studied in 14 whole milk samples, and the highest selenium levels were found in milk whey (47.2-73.6%), while the lowest level was found for the fat phase (4.8-16.2%). A strong correlation was found between the selenium levels in whole milk and the selenium levels in the milk components.
Asunto(s)
Análisis de los Alimentos , Lactancia , Leche/química , Selenio/análisis , Espectrofotometría Atómica/métodos , Animales , Bovinos , Grasas/química , Femenino , Factores de TiempoRESUMEN
Fundamento y objetivo: La enfermedad mineral ósea (EMO) es más frecuente en pacientes con fenilcetonuria. Los objetivos del estudio son conocer la utilidad de los marcadores de remodelado óseo para identificar a pacientes con fenilcetonuria con EMO y conocer las alteraciones del remodelado óseo subyacentes. Pacientes y método: Estudio observacional transversal de 43 pacientes con fenilcetonuria > 7 años (extremos 7,1-41 años). Se realizó encuesta nutricional, densitometría, determinación de fosfatasa alcalina ósea (FAO), procollagen type 1 N-terminal propeptide (PNP-1, «propéptido aminoterminal del procolágeno tipo 1»), beta-crosslaps y relación calcio/creatinina en orina. Se estratificó a los pacientes por edad y tipo de tratamiento. Resultados: El 20,9% de los pacientes presentaron marcadores de remodelado óseo patológicos; el 90% de ellos eran adultos. La FAO estaba disminuida en el 70% de ellos, y el beta-crosslaps en el 42,8%. Los valores de FAO fueron patológicos con más frecuencia en diagnosticados de fenilcetonuria tardíamente (41,7 frente a 10,7%; p < 0,05) y en pacientes con EMO (60 frente a 14,3%; p < 0,05). Los valores de PNP-1 y calcio/creatinina fueron similares entre todos los pacientes con fenilcetonuria independientemente de presentar EMO, diagnóstico tardío o tratamiento con tetrahidrobiopterina. Los pacientes con disminución de FAO y beta-crosslaps recibieron menor ingesta de proteínas naturales: FAO (media [DE] de 0,21 [0,13] frente a 0,65 [0,65] g/kg; p < 0,05); beta-crosslaps (media de 0,29 [0,23] frente a 0,65 [0,66] g/kg; p < 0,05). Ninguno de los tratados con tetrahidrobiopterina presentó valores alterados de marcadores óseos. Conclusiones: Los pacientes adultos fenilcetonúricos con menor ingesta de proteínas naturales tienden a presentar valores disminuidos de FAO, marcador que puede resultar útil para identificar a los pacientes con riesgo de presentar EMO (AU)
Background and objective: Mineral bone disease is more common in phenylketonuric patients. The objectives of this study were to determine the usefulness of biochemical bone markers to identify phenylketonuric patients with mineral bone disease (MBD) and know the underlying bone remodeling alterations. Patients and method: Cross-sectional study of 43 phenylketonuric patients > 7 years (range: 7.1-41 years). A nutritional survey was performed and bone alkaline phosphatase (BAP), procollagen type 1 N-terminal propeptide (PNP-1), beta-crosslaps and ratio calcium/creatinine in urine were determined. Results: A percentage of 20.9 of patients had pathological biochemical bone markers, 90% of them being adults. BAP was decreased in 70% of them and beta-crosslaps in 42.8%. BAP values were more often pathological in phenylketonuric patients with a late diagnosis (41.7 vs. 10.7%; P < .05) and in patients with MBD (60 vs. 14.3%; P < .05). PNP-1 values and calcium/creatinine were similar among all phenylketonuric patients regardless of presenting MBD, late diagnosis or tetrahydrobipterin treatment (enzyme cofactor). Patients with decreased BAP and beta-crosslaps had lower natural protein intake: BAP (0.21 ± 0.13 vs. 0.65 ± 0.65 g/kg; P < .05); beta-crosslaps (0.29 ± 0.23 vs. 0.65 ± 0.66 g/kg; P < .05). None of the tetrahydrobiopterin treated patients showed altered values of BAP, PNP-1 or calcium/creatinine. Conclusions: Adult phenylketonuric patients with lower natural protein intake tend to have lower values of BAP, which is a marker that may be useful to identify patients at risk for MBD (AU)
Asunto(s)
Humanos , Masculino , Femenino , Adolescente , Adulto , Niño , Remodelación Ósea/fisiología , Biomarcadores/metabolismo , Enfermedades Óseas Metabólicas/diagnóstico , Fenilcetonurias , Biomarcadores/sangre , Biomarcadores/orina , Enfermedades Óseas Metabólicas/sangre , Enfermedades Óseas Metabólicas/orina , Estudios TransversalesRESUMEN
This paper describes the development of an electrophoretic method used to analyse diuretics, and its use in the analysis of pharmaceutical formulations. Chlorthalidone, furosemide, hydrochlorothiazide and triamterene were separated in 5 min by micellar electrokinetic capillary chromatography using a carrier containing sodium dodecylsulphate as surfactant, and were subsequently detected spectrophotometrically using a diode-array detector. The limits of detection (S/N=3) were in all cases less than 1.2 mugml(-1) for all compounds. Satisfactory repeatability was obtained for migration times (<1.6%) and corrected peak areas (<5.3%) in the analysis of pharmaceutical formulations. The reproducibility was less than 4% for all samples tested. The average recoveries obtained, which ranged between 97 and 100%, testify to the accuracy of the proposed method.